Biomarin Pharmaceutical
BMRN
55.20
-1.02
-1.81%
Biomarin Pharmaceutical
US · BMRN
#1379 by market cap
Listed 1970
55.20
-1.02
-1.81%
Live - 5344 symbols - heartbeat 107s ago
· 2026-10-08 07:00
Pre-market
55.05
-0.27%
After-hours
55.55
+0.63%
- Market cap
- 10.69B
- P/E (TTM)i
- 145.26
- P/Bi
- 1.69
- EPSi
- 1.80
- Div yieldi
- 0.00%
- 52W posi
- 27%
Reader sentiment
Are you bullish or bearish on BMRN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 6 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 102.45% -0.12pp
- Institutions
- 674 -6
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund71.95%
Hedge Fund18.67%
Sovereign Wealth Fund4.25%
Public Company2.10%
VC/PE Fund1.92%
Government Pension Fund1.91%
Private Company0.73%
Insurance Company0.66%
Individual/Insider0.40%
Top holders as of 2026-06-30
BlackRock
10.56% · 20.45M sh
Dodge & Cox
7.67% · 14.84M sh
PRIMECAP Management Company
7.33% · 14.19M sh
Vanguard Capital Management, LLC
5.15% · 9.97M sh
Vanguard Portfolio Management, LLC
4.47% · 8.65M sh
Norges Bank Investment Management
4.24% · 8.21M sh
State Street Global Advisors
4.03% · 7.80M sh
Viking Global Investors LP
3.93% · 7.62M sh
Vestal Point Capital, LP
3.11% · 6.03M sh
AQR Capital Management
2.93% · 5.68M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 20 sells
| Name | Role | Stake |
|---|---|---|
| Richard Meier | Lead Independent Director | 0.07% |
| Elaine Heron | Independent Director | 0.05% |
| Brian Mueller | Chief Financial Officer | 0.04% |
| George Davis | Chief Legal Officer | 0.03% |
| Alexander Hardy | Chief Executive Officer | 0.03% |
| C. Guyer | Chief Technical Officer of Manufacturing & Technical Operations | 0.03% |
| Gregory Friberg | Executive VP and Chief Research & Development Officer | 0.02% |
| David E. Pyott | Independent Director | 0.02% |
| Robert Hombach | Independent Director | 0.02% |
| Elizabeth Anderson | Independent Director | 0.02% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-29 | Gregory Friberg | Executive VP and Chief Research & Development Officer | Sale to Issuer | -4,086 | $60.00 |
| 2026-09-09 | Robert Plenge | Independent Director | Other Acquisition | +6,140 | -- |
| 2026-09-01 | George Davis | Chief Legal Officer | Open Market Disposition | -17,557 | $66.28 |
| 2026-06-01 | Mark Enyedy | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Ian T. Clark | Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Willard Dere | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Timothy Walbert | Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Maykin Ho | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Robert Hombach | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Athena Countouriotis | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Elizabeth Anderson | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-06-01 | Barbara Bodem | Independent Director | Other Acquisition | +7,490 | -- |
| 2026-05-19 | Cristin Hubbard | Executive Vice President | Sale to Issuer | -2,318 | $50.20 |
| 2026-05-06 | Gregory Friberg | Executive VP and Chief Research & Development Officer | Open Market Disposition | -3,281 | $53.85 |
| 2026-03-17 | George Davis | Chief Legal Officer | Sale to Issuer | -1,273 | $56.05 |
| 2026-03-16 | Alexander Hardy | Chief Executive Officer | Sale to Issuer | -4,252 | $56.05 |
| 2026-03-16 | Brian Mueller | Chief Financial Officer | Sale to Issuer | -2,117 | $56.05 |
| 2026-03-16 | Gregory Friberg | Executive VP and Chief Research & Development Officer | Sale to Issuer | -1,629 | $56.05 |
| 2026-03-16 | Cristin Hubbard | Executive Vice President | Sale to Issuer | -1,245 | $56.05 |
| 2026-03-16 | C. Guyer | Chief Technical Officer of Manufacturing & Technical Operations | Sale to Issuer | -1,693 | $56.05 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:00 · For reference only, not investment advice and not tailored to your situation.